Previous 10 | Next 10 |
Momenta Pharmaceuticals (NASDAQ: MNTA ) is up 5.1% after hours, building on day's gains of 23.7% after JPMorgan raised its rating to Overweight. More news on: Momenta Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: FLNT +59.8% . OGI +27.8% . APTX +9.3% . MNTA +4.8% . OTCQB:CURR +2.0% . More news on: Fluent, Inc., OrganiGram Holdings Inc., Aptinyx Inc., Stocks on the move, , Read more ...
-- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled; readout expected in Q3 2020 – -- Expanding pipeline of novel therape...
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
Momenta Pharmaceuticals (NASDAQ: MNTA ) CFO Michelle Robertson will resign effective January 8 to pursue other opportunities. More news on: Momenta Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc . (Nasdaq: MNTA) (“Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated disease...
CAMBRIDGE, Mass., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2020 at 3:00 p.m...
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors. “Dr. Barlow’s expertise in market access and commercial pricing will be in...
Momenta Pharmaceuticals (NASDAQ: MNTA ) has priced its public offering of 14,516,130 common shares at $15.50 per share, for gross proceeds of ~$225M. More news on: Momenta Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common stock at the public offering price of $15.50 per share for total gross proceeds to Momenta of a...
News, Short Squeeze, Breakout and More Instantly...
Momenta Pharmaceuticals Inc. Company Name:
MNTA Stock Symbol:
NASDAQ Market:
Momenta Pharmaceuticals Inc. Website:
Are These Top 3 Pharmaceutical Stocks On Your October Watchlist? Investing in pharmaceutical stocks is a popular trend in times of political or economic instability. This is because the demand for drugs will still be steady all year long, no matter what is happening in the world...
Chesapeake Utilities to Join S&P SmallCap 600 Chesapeake Utilities to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 25, 2020 NEW YORK , Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta Pharmaceuticals In...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...